Acme Universal Safezone 9 IPO
Acme Universal Safezone 9 IPO is an SME IPO raising ₹36 Cr at ₹65 – ₹71 a share. It listed on 6 Oct 2026 at ₹101, +42.3% against its issue price of ₹71, and trades at ₹102 today (+43.7% since issue). It was subscribed 16× in total.
15.6 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
What this company actually does
Read out of the prospectus’s business section, stripped of its marketing language.
Acme Universal Safezone 9 Limited manufactures and supplies industrial safety footwear under the brand name 'ACME'. It operates in the Personal Protective Equipment (PPE) segment, selling safety footwear to end-users in construction, oil and gas, mining, heavy engineering, automotive, pharmaceuticals, chemical processing, foundry, and power generation. The company runs four manufacturing facilities in Madhya Pradesh and Uttar Pradesh, and sells 15 product lines spanning EVA-rubber, Nitrile Rubber, and PVC sole variants compliant with IS 15298, EN ISO 20345, ASTM F2413, and SEDEX SMETA standards.
How it earns
Primarily by manufacturing and selling branded industrial safety footwear (with custom design based on customer data) through three channels: direct institutional sales under long-term rate contracts, regional distributors and dealers, and digital/e-commerce platforms, supplemented by exports to overseas distributors and buying agents.
Who buys
Customer names are not disclosed in the text. Stated revenue concentration from operations for FY 25-26: Top 1 customer 12.13%, Top 3 customers 23.01%, Top 5 customers 31.74%, Top 10 customers 47.71%. Top export geographies were UAE (3.30%), Nigeria (1.76%), Israel (1.72%), and Bahrain (0.40%); top domestic states were Maharashtra (15.67%), Tamil Nadu (13.58%), Gujarat (13.30%), Uttar Pradesh (12.01%), and Odisha (6.61%) of total revenue from operations.
Scale
FY 25-26 Revenue from Operations ₹20,590.31 lakhs (≈₹205.90 crore; 1 crore = 100 lakh); 4 manufacturing facilities (1 owned, 3 leased) in Madhya Pradesh and Uttar Pradesh; installed capacity 43,15,000 units per annum with 64.23% utilisation; 1,073 employees as of March 31, 2026 (1,038 in Operations); channel-partner warehousing at more than 40 locations in India; exports to 10+ countries.
What it says sets it apart
- Four in-house manufacturing facilities covering all production stages (cutting, upper assembly, lasting, sole production/injection, finishing, packaging) in Madhya Pradesh and Uttar Pradesh, providing control over scheduling and quality
- Automated production using Desma PU direct injection machines (Germany), Orisol automated stitching machines, triple density manufacturing technology, Phylon rubber processing, and Surge Sense technology, integrated with SAP S/4 HANA across manufacturing units
- 15 product lines compliant with multiple standards (IS 15298, EN ISO 20345, ASTM F2413, SEDEX SMETA), enabling both domestic institutional and export orders from the same production infrastructure without dedicated export-only lines
- In-house R&D unit and product testing laboratory with ICad3D-based visualisation, supporting material innovation, structural design, new variants, and batch-wise compliance testing
- Multi-channel distribution across India with channel-partner warehousing at more than 40 locations covering cities including New Delhi, Mumbai, Pune, Hyderabad, Bengaluru, Chennai, Kolkata, Ahmedabad, Indore, and Bhopal, combined with export presence in UAE, Bahrain, Saudi Arabia, Nigeria, Israel, Netherlands, Hong Kong, Cameroon, and Mauritius
Revenue mix
The numbers at a glance
The price they’re asking →derived: cut-off price Rs71 / stated EPS Rs4.17 (FY2026 (year ended March 31, 2026) Diluted EPS, as per Restated Financial Statements). Stated figures are as printed in the prospectus; margins, growth and the borrowing ratio are computed from its own summary table. A multiple is one lens, not a verdict.
The last few years in numbers
From the prospectus’s own summary financial table (restated standalone). Margins and growth are computed from the stated figures; everything else is as printed.
| Period | Revenue | Profit after tax | PAT margin | Net worth | Borrowings |
|---|---|---|---|---|---|
| FY2026 | ₹206 Cr+10% | ₹6 Cr+628% | 2.8% | ₹53 Cr | ₹58 Cr |
| FY2025 | ₹187 Cr+5% | ₹1 Cr-89% | 0.4% | ₹47 Cr | ₹50 Cr |
| FY2024 | ₹179 Cr | ₹8 Cr | 4.2% | ₹42 Cr | ₹45 Cr |
Where the money goes
The offer →Most of this issue is new shares — the money raised goes to the company, not to exiting shareholders.
How its cohort has done
185 SME issues listed in 2026 that we can price today. This is the group this issue belongs to.
Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →
How the book finished
The category split is the number worth reading, not the total.
Demand is spread fairly evenly across investor categories.
What we hold for this issue
Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.
What could go wrong
All 13 risks & documents →From the register read out of the issuer’s own prospectus — each item is quoted verbatim with its page on the risks tab.
What happens when
Next: the UPI mandate expires on 11 Nov 2026.
What to watch
- Priced at 17× earnings — 58% below the median of the peers the issuer itself names.
- The register's top risk: BIS IS 15298 license is critical for government tenders (prospectus page 33).
- Its cohort's record: median −2.7% since issue price, 51.9% now below it — a base rate, not a forecast.
Each line restates a disclosure from the prospectus or the exchanges — nothing here is a recommendation to apply to this issue.
Track Acme Universal Safezone 9 Limi
Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.
Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.